Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

Post by ready2go1on Nov 12, 2012 10:34am
274 Views
Post# 20588307

quick double

quick double

Difficult to assess the situation without any news and I am not sure that Hologic will get into specific #'s when they report this evening, but I continue to hear positive comments from the end users of pca3. I toured a lab last week and was impressed by the volume of pca3 tests that they ran in October. (I was not at the lab for pca3 but I did ask more than a few questions about the marker, enough that they asked me if I wanted a test)

We sit at this crazy levels secondary to fear of the unknown and small market sell orders from several  weeks/months ago. It is difficult to pick up any number of shares without moving the share price 20%. I expect hologic to come out with a game plan for PCA3 a few weeks after this earnings report; there are several options that they have and they all will be positive for Diagnocure.

I am looking for a quick double on the release of news and than I see us between the $1.20 and $1.60 range. I went to a recent football game with friends of mine who are Urologists and I told them to stick any future stock picks they have in their A--,because this has been a waste of my time and money.

I have learned how long it takes for good drugs,markers, and tests to get to the people who would benefit from them in our health care system but it has not been worth the $'s I have sitting on the table.

I have more to say but I will wait.

<< Previous
Bullboard Posts
Next >>